Literature DB >> 26664111

Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression.

Michael R Crager1, Gong Tang2.   

Abstract

We propose a method for assessing an individual patient's risk of a future clinical event using clinical trial or cohort data and Cox proportional hazards regression, combining the information from several studies using meta-analysis techniques. The method combines patient-specific estimates of the log cumulative hazard across studies, weighting by the relative precision of the estimates, using either fixed- or random-effects meta-analysis calculations. Risk assessment can be done for any future patient using a few key summary statistics determined once and for all from each study. Generalizations of the method to logistic regression and linear models are immediate. We evaluate the methods using simulation studies and illustrate their application using real data.

Entities:  

Keywords:  Cox proportional hazards regression; meta-analysis; patient-specific meta-analysis; risk assessment

Year:  2014        PMID: 26664111      PMCID: PMC4673004          DOI: 10.1080/02664763.2014.925102

Source DB:  PubMed          Journal:  J Appl Stat        ISSN: 0266-4763            Impact factor:   1.404


  9 in total

1.  Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Stat Med       Date:  2002-08-15       Impact factor: 2.373

2.  Random-effects model for meta-analysis of clinical trials: an update.

Authors:  Rebecca DerSimonian; Raghu Kacker
Journal:  Contemp Clin Trials       Date:  2006-05-12       Impact factor: 2.226

3.  Randomisation and baseline comparisons in clinical trials.

Authors:  D G Altman; C J Doré
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

4.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

5.  Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials.

Authors: 
Journal:  Lancet       Date:  2001-10-20       Impact factor: 79.321

6.  Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-09-19       Impact factor: 79.321

7.  Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.

Authors:  Mitch Dowsett; Jack Cuzick; Christopher Wale; John Forbes; Elizabeth A Mallon; Janine Salter; Emma Quinn; Anita Dunbier; Michael Baum; Aman Buzdar; Anthony Howell; Roberto Bugarini; Frederick L Baehner; Steven Shak
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

8.  Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.

Authors:  Gong Tang; Jack Cuzick; Joseph P Costantino; Mitch Dowsett; John F Forbes; Michael Crager; Eleftherios P Mamounas; Steven Shak; Norman Wolmark
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

Review 9.  Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.

Authors:  Grace M Callagy; Mark J Webber; Paul D P Pharoah; Carlos Caldas
Journal:  BMC Cancer       Date:  2008-05-29       Impact factor: 4.430

  9 in total
  3 in total

1.  Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.

Authors:  Greg Yothers; Alan P Venook; Eiji Oki; Donna Niedzwiecki; Yan Lin; Michael R Crager; Calvin Chao; Frederick L Baehner; Norman Wolmark; Takayuki Yoshino
Journal:  J Gastrointest Oncol       Date:  2022-02

2.  Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies.

Authors:  E Rakovitch; R Gray; F L Baehner; R Sutradhar; M Crager; S Gu; S Nofech-Mozes; S S Badve; W Hanna; L L Hughes; W C Wood; N E Davidson; L Paszat; S Shak; J A Sparano; L J Solin
Journal:  Breast Cancer Res Treat       Date:  2018-01-31       Impact factor: 4.872

3.  Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer.

Authors:  Joseph A Sparano; Michael R Crager; Gong Tang; Robert J Gray; Salomon M Stemmer; Steven Shak
Journal:  J Clin Oncol       Date:  2020-12-11       Impact factor: 50.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.